Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seidel, C.
Right arrow Articles by e Nordic Myeloma Study Group, A. W. f. t.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seidel, C.
Right arrow Articles by e Nordic Myeloma Study Group, A. W. f. t.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma

Carina Seidel, Magne Børset, Ingemar Turesson, Niels Abildgaard, Anders Sundan, and Anders Waage for th e Nordic Myeloma Study Group

From the Institute of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway; the Department of Medicine, Malmö University Hospital, Malmö, Sweden; the Department of Medicine and Hematology, Aarhus University Hospital, Aarhus, Denmark; and the Section of Hematology, University Hospital, Norwegian University of Science and Technology, Trondheim, Norway.

Serum from 398 myeloma patients at diagnosis and serial samples from 29 patients were analysed for hepatocyte growth factor (HGF). HGF was elevated at diagnosis in 43% of myeloma patients compared with healthy controls (median 1.00 ng/mL and 0.44 ng/mL, respectively; P < .00001). In the group with elevated HGF levels 46% of the patients reached plateau phase, as compared with 60% of the patients with low HGF levels (P = .005), and the median survival time was 21 and 32 months, respectively (P = .002). In a univariate Cox regression analysis, HGF was a significant predictor of mortality (P = .02). In the subgroup of patients with beta 2-microglobulin levels less than or equal to 6 mg/L, high versus low HGF was a prognostic factor when a multivariate Cox regression analysis was performed. In serial samples HGF was higher at the time of diagnosis and relapse (median 0.57 ng/mL and 0.52 ng/mL, respectively; P = .0018) than at response (median 0.24 ng/mL, P = .008). We conclude that HGF may be a useful follow-up parameter in myeloma patients. Measurement of HGF may identify a group of patients with poor response to melphalan-prednisone treatment and short survival. HGF was a prognostic factor in patients with high levels of beta 2-microglobulin.

Blood, Vol. 91 No. 3 (February 1), 1998: pp. 806-812
© 1998 by The American Society of Hematology.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Anticancer ResHome page
E. G. SKOLDENBERG, A. LARSSON, A. JAKOBSON, F. HEDBORG, P. KOGNER, R. H. CHRISTOFFERSON, and F. AZARBAYJANI
The Angiogenic Growth Factors HGF and VEGF in Serum and Plasma from Neuroblastoma Patients
Anticancer Res, August 1, 2009; 29(8): 3311 - 3319.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Hose, J. Moreaux, T. Meissner, A. Seckinger, H. Goldschmidt, A. Benner, K. Mahtouk, J. Hillengass, T. Reme, J. De Vos, et al.
Induction of angiogenesis by normal and malignant plasma cells
Blood, July 2, 2009; 114(1): 128 - 143.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
R. U. Holt, U.-M. Fagerli, V. Baykov, T. B. Ro, H. Hov, A. Waage, A. Sundan, and M. Borset
Hepatocyte growth factor promotes migration of human myeloma cells
Haematologica, April 1, 2008; 93(4): 619 - 622.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. Stellrecht, C. J. Phillip, F. Cervantes-Gomez, and V. Gandhi
Multiple Myeloma Cell Killing by Depletion of the MET Receptor Tyrosine Kinase
Cancer Res., October 15, 2007; 67(20): 9913 - 9920.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Standal, N. Abildgaard, U.-M. Fagerli, B. Stordal, O. Hjertner, M. Borset, and A. Sundan
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma
Blood, April 1, 2007; 109(7): 3024 - 3030.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Du, Y. Hattori, T. Yamada, K. Matsumoto, T. Nakamura, M. Sagawa, T. Otsuki, T. Niikura, T. Nukiwa, and Y. Ikeda
NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor
Blood, April 1, 2007; 109(7): 3042 - 3049.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
T. Watanabe, M. Tsuda, Y. Makino, S. Ichihara, H. Sawa, A. Minami, N. Mochizuki, K. Nagashima, and S. Tanaka
Adaptor Molecule Crk Is Required for Sustained Phosphorylation of Grb2-Associated Binder 1 and Hepatocyte Growth Factor-Induced Cell Motility of Human Synovial Sarcoma Cell Lines
Mol. Cancer Res., July 1, 2006; 4(7): 499 - 510.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Ohnishi, K. Kakimoto, K. Bandow, C. J. Lowenstein, Y. Daikuhara, and T. Matsuguchi
Mature Hepatocyte Growth Factor/Scatter Factor on the Surface of Human Granulocytes Is Released by a Mechanism Involving Activated Factor Xa.
J. Immunol., June 1, 2006; 176(11): 6945 - 6953.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. P. M. Tjin, R. W. J. Groen, I. Vogelzang, P. W. B. Derksen, M. D. Klok, H. P. Meijer, S. van Eeden, S. T. Pals, and M. Spaargaren
Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma
Blood, January 15, 2006; 107(2): 760 - 768.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Uehara, K. Muramoto, T. Imamura, K. Nakayama, J. Potempa, J. Travis, S. Sugawara, and H. Takada
Arginine-Specific Gingipains from Porphyromonas gingivalis Stimulate Production of Hepatocyte Growth Factor (Scatter Factor) through Protease-Activated Receptors in Human Gingival Fibroblasts in Culture
J. Immunol., November 1, 2005; 175(9): 6076 - 6084.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. P. M. Tjin, R. J. Bende, P. W. B. Derksen, A.-P. van Huijstee, H. Kataoka, M. Spaargaren, and S. T. Pals
Follicular Dendritic Cells Catalyze Hepatocyte Growth Factor (HGF) Activation in the Germinal Center Microenvironment by Secreting the Serine Protease HGF Activator
J. Immunol., September 1, 2005; 175(5): 2807 - 2813.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Hov, R. U. Holt, T. B. Ro, U.-M. Fagerli, H. Hjorth-Hansen, V. Baykov, J. G. Christensen, A. Waage, A. Sundan, and M. Borset
A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells
Clin. Cancer Res., October 1, 2004; 10(19): 6686 - 6694.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. P.M. Tjin, P. W.B. Derksen, H. Kataoka, M. Spaargaren, and S. T. Pals
Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator
Blood, October 1, 2004; 104(7): 2172 - 2175.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, R. Shringarpure, T. Hideshima, M. Akiyama, D. Chauhan, N. Munshi, X. Gu, et al.
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
PNAS, January 13, 2004; 101(2): 540 - 545.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
X. Wang, P. Le, C. Liang, J. Chan, D. Kiewlich, T. Miller, D. Harris, L. Sun, A. Rice, S. Vasile, et al.
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion
Mol. Cancer Ther., November 1, 2003; 2(11): 1085 - 1092.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Rehman, R. V. Considine, J. E. Bovenkerk, J. Li, C. A. Slavens, R. M. Jones, and K. L. March
Obesity is associated with increased levels of circulating hepatocyte growth factor
J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1408 - 1413.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
O. Sezer, U. Heider, I. Zavrski, C. A. Kuhne, and L. C. Hofbauer
RANK ligand and osteoprotegerin in myeloma bone disease
Blood, March 15, 2003; 101(6): 2094 - 2098.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Standal, M. Borset, S. Lenhoff, F. Wisloff, B. Stordal, A. Sundan, A. Waage, and C. Seidel
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
Blood, December 1, 2002; 100(12): 3925 - 3929.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. E. I. Taher, E. P. M. Tjin, E. A. Beuling, J. Borst, M. Spaargaren, and S. T. Pals
c-Cbl Is Involved in Met Signaling in B Cells and Mediates Hepatocyte Growth Factor-Induced Receptor Ubiquitination
J. Immunol., October 1, 2002; 169(7): 3793 - 3800.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. W. B. Derksen, R. M. J. Keehnen, L. M. Evers, M. H. J. van Oers, M. Spaargaren, and S. T. Pals
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma
Blood, February 15, 2002; 99(4): 1405 - 1410.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Seidel, M. Borset, O. Hjertner, D. Cao, N. Abildgaard, H. Hjorth-Hansen, R. D. Sanderson, A. Waage, and A. Sundan
High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity
Blood, November 1, 2000; 96(9): 3139 - 3146.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Borset, O. Hjertner, S. Yaccoby, J. Epstein, and R. D. Sanderson
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins
Blood, October 1, 2000; 96(7): 2528 - 2536.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Michigami, N. Shimizu, P. J. Williams, M. Niewolna, S. L. Dallas, G. R. Mundy, and T. Yoneda
Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha 4beta 1-integrin enhances production of osteoclast-stimulating activity
Blood, September 1, 2000; 96(5): 1953 - 1960.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. Gohji, M. Nomi, Y. Niitani, S. Kitazawa, A. Fujii, Y. Katsuoka, and M. Nakajima
Independent Prognostic Value of Serum Hepatocyte Growth Factor in Bladder Cancer
J. Clin. Oncol., August 16, 2000; 18(16): 2963 - 2971.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Seidel, A. Sundan, M. Hjorth, I. Turesson, I. M. S. Dahl, N. Abildgaard, A. Waage, and M. Borset
Serum syndecan-1: a new independent prognostic marker in multiple myeloma
Blood, January 15, 2000; 95(2): 388 - 392.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
O. Hjertner, M. L. Torgersen, C. Seidel, H. Hjorth-Hansen, A. Waage, M. Borset, and A. Sundan
Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease
Blood, December 1, 1999; 94(11): 3883 - 3888.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020